Hello Folks, today Medgadget added a video (see below) presentation on "Microsulis microwave ablation (MWA) system" which is used to destroy liver tumors by heat generated microwave energy. The device is beneficial when liver tumors can not be removed surgically. The advantages of MWA over RFA (Radiofrequency Ablation) are highlighted below
.
***Update Dec 6th
Liver Cancer:First U.S. Patient Treated with the Accu2i Percutaneous Microwave Tissue Ablation Device
.
What Is Primary Liver Cancer?
Microwave ablation (MWA) is used to treat inoperable liver tumors.
These include hepatocellular carcinoma or (primary liver cancer) that originates in the liver.
HCC (hepatocellular carcinoma) is a disease associated with cirrhosis and hepatitis B and C .
What Is Secondary Liver Cancer ?
Metastatic or secondary liver cancer results through the spread of cancer from another organ in the body, Because the liver has two blood supplies and a ready store of growth factors, it is a fertile site for liver metastases, liver tumors originating elsewhere in the body. Abdominal cancers, and especially colorectal cancer, frequently metastasize to the liver.
What Is Microwave ablation (MWA) ?
A new technology, microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. With microwave ablation, the surgeon inserts a small laparoscopic port or open incision to access the tumor. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
,What Are The Advantages Over Traditional RFA= Radiofrequency Ablation ?
"According to the American Cancer Society, more than 450,000 Americans suffer from lung and liver cancer annually. Historically treatment options for these types of cancer have included one or a combination of treatments including surgical removal of the cancer, chemotherapy, radiofrequency ablation (RFA), or radiation therapy. Ablative therapies which aim to destroy tumors in-situ are limited by the number and size of the tumors that can be targeted and so it’s not an option in many cases due to the limited performance of existing RFA and microwave systems. However the Acculis Accu2i pMTA system is the first high power 2.45 GHz system that enables larger and faster ablations to be performed. This means that ablative therapy will now be available as an option for many more patients".
Microwave ablation has a number advantages when compared to traditional RFA, which is a standard method for ablating liver tumors
These include:
Speed - Microwave ablation (MWA) is faster than RFA, destroying tumors more efficiently, and reducing the time patients remain under general anesthesia.
Simultaneous Tumor Ablation - With MWA, surgeons can ablate multiple liver tumors at the same time.
Larger Tumor Size - MWA can ablate larger tumors than are possible with RFA.
,
What Is Radiofrequency Ablation (RFA) Therapy ?
How is RFA done and how does it work?
In RFA, heat is generated locally by a high frequency, alternating current that flows from the electrodes. A probe is inserted into the center of the tumor and the non-insulated electrodes, which are shaped like prongs, are projected into the tumor. The local heat that is generated melts the tissue (coagulative necrosis) that is adjacent to the probe. The probe is left in place for about 10 to 15 minutes.
.
***Up***Update Dec 6thdate Dec 6th
Liver Cancer:First U.S. Patient Treated with the Accu2i Percutaneous Microwave Tissue Ablation Device,
Microsulis Reports Comprehensive Global Electrical Safety Standards for Powerful Accu2i Percutaneous Microwave Tissue Ablation System
Nov 11 2010
“Increasing numbers of clinicians around the world are adopting the radically improved performance and ease of use of the Acculis system, moving away from older radiofrequency ablation systems. The groundbreaking performance of the device reflects the extensive testing the device has undergone to the highest standards around the world.”
The Accu2i pMTA is the most powerful tumour ablation system currently available, combining extreme ease of use with the widest range of clinical applications. The device is a single high power high frequency 2.45GHz microwave needle that can address tumours over 5cm in size in just 6 minutes, and is therefore between 3 to 10 times faster than other systems. Its launch followed two years of extensive clinical use and evaluation in major centres around the world mainly treating liver and lung cancers
Acculis Microwave Thermal Ablation Demo at RSNA 2010
Press Release In August
August 16, 2010 09:11 AM Eastern Time
Microsulis Medical Limited Receives FDA 510(k) Clearance of Accu2i Percutaneous Microwave Tissue Ablation Device
*** August
High Power Microwave Tissue Ablation System Used to Destroy Liver and Lung Tumors
DENMEAD, England--(BUSINESS WIRE)--Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that the U.S. Food and Drug Administration (FDA) has provided the company 510(k) clearance to market the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures. This innovative treatment allows physicians to apply precise microwave energy to ablate unwanted tissue masses. The system has already been in use in Europe treating liver and lung tumors via a small 1.8 mm needle puncture of the skin. By providing an alternative to “open surgery” patients avoid the risks associated with longer, more invasive surgical interventions.
“If the clinical performance of the system confirms the early promise of this technology, this advancement will lead to new treatment options for lung and liver cancer patients”
“We are delighted to receive this clearance from the FDA and are looking forward to introducing the pMTA product to the U.S. market after seeing its success throughout Europe. Having transferred the product to the manufacturer in Europe we now have a system that we know is market-ready and tested,” said Stuart McIntyre, CEO of Microsulis Medical Limited. “Moreover this is the first high power 2.45 GHz system available and sets a new benchmark for such devices.”
According to the American Cancer Society, more than 450,000 Americans suffer from lung and liver cancer annually. Historically treatment options for these types of cancer have included one or a combination of treatments including surgical removal of the cancer, chemotherapy, radiofrequency ablation (RFA), or radiation therapy. Ablative therapies which aim to destroy tumors in-situ are limited by the number and size of the tumors that can be targeted and so it’s not an option in many cases due to the limited performance of existing RFA and microwave systems. However the Acculis Accu2i pMTA system is the first high power 2.45 GHz system that enables larger and faster ablations to be performed. This means that ablative therapy will now be available as an option for many more patients.
“If the clinical performance of the system confirms the early promise of this technology, this advancement will lead to new treatment options for lung and liver cancer patients,” said Dr. William Scott Helton, Chairman, Department of Surgery at Hospital of Saint Raphael, New Haven, Conn. “The Accu2i pMTA system allows physicians to deliver precise microwave energy to treat tumors up to 5cm in size in a very short period of time. It will add a significant additional tool into the armamentarium of oncologists, surgeons and radiologists treating patients with this illness.”
For more information about the Acculis Accu2i pMTA system, visit About Microsulis Medical Limited
Founded in 1997, Microsulis Medical Ltd is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic devices. The company was initially formed following research collaboration between Chemring and the University of Bath in 1993. The company leads the field in microwave technology for endometrial ablation, tumour ablation and venous occlusion. Part of MML, Acculis specialises in devices for oncology applications.
Information On This Blog For Liver Cancer ; Treatments
HCV And HCC Updates: ThermoDox® To Treat Primary Liver Cancer
.,
my dad had liver microwave ablation on his liver and developed a bile duct which turned to peritonitus and then septicimia and he passed away 9 days after having the surgery
ReplyDeleteI am sorry, thank you for posting.
ReplyDeleteI have had microwave ablation on a metastasis on my liver (originated from my abdomen). What are the side effects of this surgery and recovery time please.
ReplyDeleteMy colon cancer spread to my liver. I have had 2 microwave ablations and 1 radio frequency ablation and experienced little discomfort. I was up and about within a few hours. I was sedated, not under general anesthesia. I am very interested in the newer, safer sounding Acculis Accu2i offered by Microsulis Ltd. for any future ablations I may need.
ReplyDelete